|
ES2740823T5
(en)
|
2008-01-15 |
2025-12-26 |
Univ Leland Stanford Junior |
Methods for manipulating phagocytosis mediated by cd47
|
|
CN105102479B
(zh)
|
2012-12-12 |
2019-06-28 |
瓦斯库劳克斯有限公司 |
治疗性cd47抗体
|
|
US9221908B2
(en)
|
2012-12-12 |
2015-12-29 |
Vasculox, Inc. |
Therapeutic CD47 antibodies
|
|
EP3575326B8
(en)
|
2012-12-17 |
2022-05-25 |
Trillium Therapeutics ULC |
Treatment of cd47+ disease cells with sirp alpha-fc fusions
|
|
WO2016015095A1
(en)
*
|
2014-07-31 |
2016-02-04 |
The University Of Western Australia |
A method for the identification of immunotherapy-drug combinations using a network approach
|
|
US11053314B2
(en)
|
2014-10-10 |
2021-07-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods to eliminate cancer stem cells by targeting CD47
|
|
US10864268B2
(en)
|
2014-11-18 |
2020-12-15 |
Janssen Pharmaceutica Nv |
CD47 antibodies, methods, and uses
|
|
CN107205368B
(zh)
|
2014-12-05 |
2020-11-17 |
瑞泽恩制药公司 |
具有人源化分化簇47基因的非人动物
|
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
US10035855B2
(en)
*
|
2015-03-04 |
2018-07-31 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind CD47
|
|
CN104804093A
(zh)
*
|
2015-05-27 |
2015-07-29 |
江苏春申堂药业有限公司 |
一种针对cd47的单域抗体
|
|
PT3341015T
(pt)
|
2015-08-26 |
2021-10-12 |
Univ Leland Stanford Junior |
Depleção incrementada de células-alvo com bloqueio de cd47 e um agonista de costimulação imunitária
|
|
US10221249B2
(en)
*
|
2015-09-10 |
2019-03-05 |
Affigen, Llc |
Method of making patient specific anti-idiotype antibodies
|
|
CN108348589B
(zh)
|
2015-09-18 |
2022-09-23 |
安驰肿瘤公司 |
治疗性cd47抗体
|
|
AU2016326423A1
(en)
|
2015-09-21 |
2018-04-26 |
Erasmus University Medical Center |
Anti-CD47 antibodies and methods of use
|
|
JP6976960B2
(ja)
|
2015-11-27 |
2021-12-08 |
カーサリクス プロプライエタリー リミテッド |
遺伝子改変された細胞およびその使用
|
|
JP7227007B2
(ja)
|
2015-12-02 |
2023-02-21 |
ストサイエンシス， インコーポレイテッド |
グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
|
|
SI3402820T1
(sl)
|
2016-01-11 |
2021-04-30 |
Forty Seven, Inc. |
Humanizirana, mišja ali himerna monoklonska protitelesa proti-CD47
|
|
CA3011429A1
(en)
*
|
2016-01-21 |
2017-07-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Treatment of cancer with combinations of immunoregulatory agents
|
|
JP2019511552A
(ja)
*
|
2016-04-15 |
2019-04-25 |
トリリウム セラピューティクス インコーポレイテッド |
Ｃｄ４７遮断療法におけるマクロファージの刺激
|
|
CN106084052B
(zh)
*
|
2016-06-17 |
2019-12-27 |
长春金赛药业股份有限公司 |
抗cd47单克隆抗体及其应用
|
|
US12344669B2
(en)
|
2016-06-17 |
2025-07-01 |
Changchun Genescience Pharmaceutical Co., Ltd. |
Anti-CD47 monoclonal antibody and use thereof
|
|
CN106117354B
(zh)
*
|
2016-06-24 |
2020-01-14 |
安徽未名细胞治疗有限公司 |
一种全人源抗CD47的全分子IgG抗体及其应用
|
|
CN110087673A
(zh)
|
2016-07-19 |
2019-08-02 |
梯瓦制药澳大利亚股份有限公司 |
抗cd47联合治疗
|
|
EP4124343A1
(en)
|
2016-10-20 |
2023-02-01 |
I-Mab Biopharma US Limited |
Novel cd47 monoclonal antibodies and uses thereof
|
|
EP3529276A4
(en)
|
2016-10-21 |
2020-06-17 |
Arch Oncology, Inc. |
CD47 THERAPEUTIC ANTIBODIES
|
|
US11446315B2
(en)
|
2016-11-03 |
2022-09-20 |
Pf Argentum Ip Holdings Llc |
Enhancement of CD47 blockade therapy by proteasome inhibitors
|
|
CN108779179B
(zh)
*
|
2016-11-28 |
2022-02-08 |
江苏恒瑞医药股份有限公司 |
Cd47抗体、其抗原结合片段及其医药用途
|
|
EP3345924A1
(en)
*
|
2017-01-10 |
2018-07-11 |
Universität Duisburg-Essen |
Use of cd47 antibodies
|
|
GB201700621D0
(en)
|
2017-01-13 |
2017-03-01 |
Guest Ryan Dominic |
Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
|
|
AU2018213718B2
(en)
|
2017-01-26 |
2022-08-25 |
Zlip Holding Limited |
CD47 antigen binding unit and uses thereof
|
|
EA201992278A1
(ru)
*
|
2017-03-27 |
2020-03-03 |
Селджин Корпорейшн |
Способы и композиции для снижения иммуногенности
|
|
CA3057718A1
(en)
*
|
2017-03-28 |
2018-10-04 |
Trillium Therapeutics Inc. |
Cd47 blockade therapy
|
|
JP7097438B2
(ja)
|
2017-07-11 |
2022-07-07 |
アクティム・セラピューティクス・インコーポレイテッド |
遺伝子操作された免疫刺激性細菌菌株およびその使用
|
|
US11401329B2
(en)
|
2017-08-02 |
2022-08-02 |
Phanes Therapeutics, Inc. |
Anti-CD47 antibodies and uses thereof
|
|
CA3072998A1
(en)
*
|
2017-08-18 |
2019-02-21 |
Ultrahuman Four Limited |
Binding agents
|
|
CN109422811A
(zh)
*
|
2017-08-29 |
2019-03-05 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
|
SI3697817T1
(sl)
|
2017-10-18 |
2023-01-31 |
Forty Seven, Inc. |
Terapija za raka jajčnikov na osnovi sredstva proti CD47
|
|
EP3704157A1
(en)
|
2017-11-01 |
2020-09-09 |
Hummingbird Bioscience Holdings Pte. Ltd. |
Cd47 antigen-binding molecules
|
|
WO2019090355A1
(en)
*
|
2017-11-06 |
2019-05-09 |
Children's National Medical Center |
Cells expressing antibodies and methods of treatment using the same
|
|
EP3706775A4
(en)
*
|
2017-11-06 |
2021-09-01 |
Trillium Therapeutics Inc. |
BLOCKING OF CD47 ASSOCIATED WITH RADIATION THERAPY
|
|
WO2019108733A2
(en)
|
2017-12-01 |
2019-06-06 |
Seattle Genetics, Inc. |
Cd47 antibodies and uses thereof for treating cancer
|
|
CN110144009B
(zh)
*
|
2018-02-14 |
2020-01-21 |
上海洛启生物医药技术有限公司 |
Cd47单域抗体及其用途
|
|
CN110305212A
(zh)
|
2018-03-27 |
2019-10-08 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
GB201804860D0
(en)
|
2018-03-27 |
2018-05-09 |
Ultrahuman Two Ltd |
CD47 Binding agents
|
|
US20210155691A1
(en)
*
|
2018-04-16 |
2021-05-27 |
Adaerata, Limited Partnership |
Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers
|
|
CN108484770B
(zh)
*
|
2018-05-16 |
2020-11-13 |
武汉云克隆科技股份有限公司 |
重组大鼠抗小鼠cd4单克隆抗体，制备方法和应用
|
|
CN110538321B
(zh)
*
|
2018-05-29 |
2023-03-10 |
江苏恒瑞医药股份有限公司 |
一种cd47抗体药物组合物及其用途
|
|
US11634490B2
(en)
|
2018-06-15 |
2023-04-25 |
Accurus Biosciences, Inc. |
Blocking antibodies against CD47 and methods of use thereof
|
|
CN110615841B
(zh)
*
|
2018-06-20 |
2022-01-04 |
瑞阳(苏州)生物科技有限公司 |
抗人cd47单克隆抗体及其应用
|
|
MX2021000165A
(es)
|
2018-07-11 |
2021-05-28 |
Actym Therapeutics Inc |
Cepas bacterianas inmunoestimuladoras modificadas y usos de las mismas.
|
|
EP3836960A4
(en)
*
|
2018-08-13 |
2022-05-11 |
Arch Oncology, Inc. |
THERAPEUTIC CD47 ANTIBODIES
|
|
WO2020047161A2
(en)
|
2018-08-28 |
2020-03-05 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
JP7583707B2
(ja)
|
2018-08-31 |
2024-11-14 |
南京聖和薬業股▲ふん▼有限公司 |
抗ｃｄ４７抗体及びその応用
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
KR20210105342A
(ko)
*
|
2018-10-29 |
2021-08-26 |
유엠씨 우트레크트 홀딩 비.브이. |
호중구의 CD47-SIRP알파 체크포인트 억제에 의한 이상 세포의 IgA 매개 사멸
|
|
EP3876977A1
(en)
|
2018-11-06 |
2021-09-15 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
|
EP3892637A1
(en)
*
|
2018-12-03 |
2021-10-13 |
Shanghai Pharmaexplorer Co., Ltd. |
Cd47 antibody, preparation method therefor and uses thereof
|
|
CA3132078A1
(en)
|
2019-03-06 |
2020-09-10 |
Jiangsu Hengrui Medicine Co., Ltd. |
Bifunctional fusion protein and pharmaceutical use thereof
|
|
US11026973B2
(en)
|
2019-04-30 |
2021-06-08 |
Myeloid Therapeutics, Inc. |
Engineered phagocytic receptor compositions and methods of use thereof
|
|
CN114206912B
(zh)
|
2019-06-07 |
2025-02-11 |
Alx肿瘤生物技术公司 |
用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂
|
|
AU2020296785A1
(en)
|
2019-06-19 |
2022-01-20 |
Lepu Biopharma Co., Ltd. |
Anti-CD47 antibodies and uses thereof
|
|
WO2020253785A1
(en)
*
|
2019-06-19 |
2020-12-24 |
Lepu Biopharma Co., Ltd. |
Anti-cd47 antibodies and uses thereof
|
|
WO2021011544A1
(en)
|
2019-07-16 |
2021-01-21 |
Gilead Sciences, Inc. |
Hiv vaccines and methods of making and using
|
|
WO2021018114A1
(zh)
*
|
2019-07-30 |
2021-02-04 |
中山康方生物医药有限公司 |
抗人p40蛋白域抗体及其用途
|
|
MX2022002613A
(es)
|
2019-09-03 |
2022-06-02 |
Myeloid Therapeutics Inc |
Metodos y composiciones para la integracion del genoma.
|
|
KR20220053665A
(ko)
*
|
2019-09-03 |
2022-04-29 |
아케소 바이오파마, 인크. |
항-cd47 단일클론 항체 및 이의 용도
|
|
EP4045083B1
(en)
|
2019-10-18 |
2024-01-10 |
Forty Seven, Inc. |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
JP7520972B2
(ja)
|
2019-10-25 |
2024-07-23 |
ウーシー バイオロジクス アイルランド リミテッド |
新規抗ｃｄ４７抗体及びその使用
|
|
CA3153636A1
(en)
|
2019-10-31 |
2021-05-06 |
Forty Seven, Inc. |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
EP4061420A1
(en)
*
|
2019-11-20 |
2022-09-28 |
Abvision, Inc. |
Monoclonal antibodies that target human cd47 protein
|
|
GB201918230D0
(en)
|
2019-12-11 |
2020-01-22 |
Prec Therapeutics Ltd |
Antibodies and their uses
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
EP4077641A1
(en)
|
2019-12-20 |
2022-10-26 |
Instil Bio (Uk) Limited |
Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
|
|
PH12022551441A1
(en)
|
2019-12-24 |
2023-11-20 |
Carna Biosciences Inc |
Diacylglycerol kinase modulating compounds
|
|
MX2022009947A
(es)
|
2020-02-14 |
2022-11-07 |
Jounce Therapeutics Inc |
Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
|
|
WO2021190441A1
(zh)
*
|
2020-03-23 |
2021-09-30 |
倍而达药业（苏州）有限公司 |
Cd47/人源化cd47抗体或其抗原结合片段、免疫活性片段及应用
|
|
CA3172449A1
(en)
|
2020-03-27 |
2021-09-30 |
Erik Hans MANTING |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
EP4130042A4
(en)
*
|
2020-04-02 |
2024-07-24 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Antigen-binding polypeptide binding to cd47, and use thereof
|
|
CN111635459B
(zh)
*
|
2020-06-27 |
2021-01-15 |
广东赛尔生物科技有限公司 |
抗cd47抗体及其在治疗癌症中的应用
|
|
KR20230033647A
(ko)
|
2020-06-30 |
2023-03-08 |
멘두스 비.브이. |
난소암 백신에서 백혈병 유래 세포의 용도
|
|
CA3200514A1
(en)
|
2020-11-03 |
2022-05-12 |
Rdiscovery, LLC |
Therapies for treatment of cancer and phagocytosis-deficiency related diseases
|
|
KR20230142828A
(ko)
*
|
2020-11-04 |
2023-10-11 |
더 트러스티즈 오브 다트마우스 칼리지 |
허혈성 및/또는 재관류 손상의 치료/예방을 위한 vista 작용제
|
|
JP2023549140A
(ja)
|
2020-11-04 |
2023-11-22 |
マイエロイド・セラピューティクス，インコーポレーテッド |
操作されたキメラ融合タンパク質組成物およびその使用方法
|
|
US20220196651A1
(en)
|
2020-12-06 |
2022-06-23 |
ALX Oncology Inc. |
Multimers for reducing the interference of drugs that bind cd47 in serological assays
|
|
EP4262828A1
(en)
|
2020-12-18 |
2023-10-25 |
Instil Bio (Uk) Limited |
Tumor infiltrating lymphocytes and anti-cd47 therapeutics
|
|
WO2022177392A1
(ko)
*
|
2021-02-19 |
2022-08-25 |
(주)샤페론 |
Cd47에 대한 단일 도메인 항체 및 이의 용도
|
|
KR20230157388A
(ko)
|
2021-03-12 |
2023-11-16 |
멘두스 비.브이. |
백신접종의 방법 및 cd47 차단의 용도
|
|
CN112979764B
(zh)
*
|
2021-03-26 |
2022-08-02 |
复旦大学附属中山医院 |
特异结合人cd47分子的多肽及其用途
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
WO2022241029A1
(en)
|
2021-05-11 |
2022-11-17 |
Myeloid Therapeutics, Inc. |
Methods and compositions for genomic integration
|
|
CN117355531A
(zh)
|
2021-06-23 |
2024-01-05 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
CN117480155A
(zh)
|
2021-06-23 |
2024-01-30 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
US11999733B2
(en)
|
2021-06-23 |
2024-06-04 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
US20230183216A1
(en)
|
2021-10-28 |
2023-06-15 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
CA3235986A1
(en)
|
2021-10-29 |
2023-05-04 |
Gilead Science, Inc. |
Cd73 compounds
|
|
AU2022417491A1
(en)
|
2021-12-22 |
2024-05-23 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
JP2024546851A
(ja)
|
2021-12-22 |
2024-12-26 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2023159220A1
(en)
*
|
2022-02-18 |
2023-08-24 |
Kenjockety Biotechnology, Inc. |
Anti-cd47 antibodies
|
|
CR20240386A
(es)
|
2022-03-17 |
2024-10-24 |
Gilead Sciences Inc |
Degradadores de dedos de zinc de la familia ikaros y usos de estos
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
AU2023256670A1
(en)
|
2022-04-21 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
CA3260083A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
CD73 COMPOUNDS
|
|
WO2024015741A1
(en)
|
2022-07-12 |
2024-01-18 |
Gilead Sciences, Inc. |
Hiv immunogenic polypeptides and vaccines and uses thereof
|
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
AU2023409398A1
(en)
|
2022-12-22 |
2025-06-05 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
AU2024259556A1
(en)
|
2023-04-21 |
2025-10-23 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025006720A1
(en)
|
2023-06-30 |
2025-01-02 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
TW202519517A
(zh)
|
2023-07-26 |
2025-05-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2025024663A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025054530A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
CN120648654A
(zh)
*
|
2024-03-13 |
2025-09-16 |
深圳太力生物技术有限责任公司 |
重组细胞的制备方法、重组细胞及其应用
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|